- Home
- MNOV vs ESLA Comparison
MNOV vs ESLA Comparison
Compare MNOV & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNOV | ESLA |
|---|---|---|
| Founded | 2000 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.4M | 45.6M |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | MNOV | ESLA |
|---|---|---|
| Price | $1.28 | $0.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $7.50 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 41.5K | 36.7K |
| Earning Date | 05-14-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,360,807.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $180.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 194.15 | N/A |
| 52 Week Low | $1.17 | $0.78 |
| 52 Week High | $1.96 | $3.15 |
Technical Indicators
Market Signals| Indicator | MNOV | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 43.04 | 36.88 |
| Support Level | $1.21 | N/A |
| Resistance Level | $1.32 | $1.31 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 40.00 | 19.37 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.